Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Sotiris Rompas, Phd
Director
Boston Healthcare Associates
Boston MA
Director, Boston Healthcare Associates, MA
Authored Items
Demonstrating Value for Biosimilars: A Conceptual Framework
Sally Amanuel, MSc, MA, MBA
,
Michael Kleinrock
,
Paola Antonini, MD, PhD
,
Victoria Coutinho, MSc, PhD
,
Thomas Goss, PharmD
,
Zhihong Lai, PhD
,
Sotiris Rompas, Phd
,
Michael F. Murphy, MD, PhD
May 2015, Vol 8, No 3
in
Practice Management
Last modified: June 3, 2015
